drugset / Trial / NCT05303038
Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.